title: Thrombophilia and varicella zoster in children.
abstract: From 2005 to 2011, 25 children of both sexes (13 boys and 12 girls, mean age 7.8 ± 2.5 years, 5-12.4 years) with acute varicella zoster virus (VZV) infection were selected. Five patients showed venous thromboembolism characterized by deep venous thrombosis (DVT). Comparison of activated partial thromboplastin time, antithrombin III, D-dimer, lupus anticoagulant, free S protein (PS), C protein, and antiphospholipid and PS antibodies was performed on children with acute VZV and DVT (group I), acute uncomplicated VZV (group II), and 30 healthy controls of both sexes (15 boys and 15 girls, mean age 7.5 ± 2.6 years, group III). Genetic thrombophilic mutations (Factor V Leiden, MTHFR C677T, and Prothrombin G20210A) were evaluated. Coagulation disorders and PS antibody were found in children with acute VZV (groups I and II). Significant differences were shown among the three groups (P < 0.05). Acute VZV infection could be associated with coagulation disorders and production of inhibitory PS antibodies in many uncomplicated cases.
authors: Department of Pediatrics, The 2nd University of Naples, Naples, Italy. mara.ferrara@unina2.it
authors: Mara
authors: M
authors: Ferrara
authors: F
authors: F
authors: Bertocco
authors: D
authors: D
authors: Ferrara
authors: L
authors: L
authors: Capozzi
mesh_terms: D017152:Antibodies, Antiphospholipid / Q000032:analysis; D000990:Antithrombin III / Q000032:analysis; D001323:Autoantibodies / Q000032:analysis; D002644:Chickenpox / Q000097:blood* / Q000150:complications / Q000821:virology; D002648:Child; D002675:Child, Preschool; D005165:Factor V / Q000235:genetics; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D014645:Herpesvirus 3, Human / Q000502:physiology; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000032:analysis; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D009154:Mutation; D010314:Partial Thromboplastin Time; D011486:Protein C / Q000032:analysis; D017293:Protein S / Q000032:analysis / Q000276:immunology; D011516:Prothrombin / Q000235:genetics; D018570:Risk Assessment; D012307:Risk Factors; D019851:Thrombophilia / Q000097:blood* / Q000150:complications / Q000235:genetics*; D054556:Venous Thromboembolism / Q000097:blood / Q000209:etiology / Q000235:genetics; D020246:Venous Thrombosis / Q000097:blood / Q000209:etiology / Q000235:genetics
chemical_list: D017152:Antibodies, Antiphospholipid; D001323:Autoantibodies; D005338:Fibrin Fibrinogen Degradation Products; D016682:Lupus Coagulation Inhibitor; D011486:Protein C; D017293:Protein S; C095381:factor V Leiden; C036309:fibrin fragment D; D000990:Antithrombin III; D005165:Factor V; D011516:Prothrombin; D042965:Methylenetetrahydrofolate Reductase (NADPH2)